Culture & Values
Subsidiaries & Joint Ventures
Diversity & Inclusion
Sustainability & ESG Report
Safety & Toxicology
Data Management and Statistical Analysis
Clinical Development Strategy
Site Management (SMO)
Medical Device / IVD
Multi-region Clinical Trial (MRCT)
Vaccine Clinical Trial
Functional Service Provider (FSP)
DreamCIS is Successfully Landed on Korea Stock Exchange
May 22, 2020
May 22, 2020
SEOUL, HANGZHOU, May 22, 2020 – DreamCIS (stock code: A223250), a Tigermed company, and a contract research organization (CRO) providing comprehensive R&D services to biopharmaceutical companies, today announced a successful landing of KOSDAQ marketing at Korea Stock Exchange (KRX) in Yeouido, Seoul.
DreamCIS is the only and first clinical CRO company that listed on the Korea Stock Exchange. Since its establishment in April 2000 in Korea, DreamCIS has been growing as a leading CRO in Korea dedicated to providing comprehensive R&D services to biopharmaceutical companies, including clinical trialoperations, post-marketing surveillance and data management.
On May 22 afternoon, a real-time online ceremony was broadcasted internally in DreamCIS, as well as the headquarters, branch offices and affiliates of its largest shareholder Tigermed, to commemorate this meaningful moment of listing on the KRX.
“To be the only and first clinical CRO listed in Korea stock market is a great milestone for our company” said Gyoungsun Kong, General Manager of DreamCIS. “It couldn’t be done without the strong support from our customers and partners, efforts from Tigermed headquarters, and most importantly the hard work and dedication of DreamCIS employees. I strongly believe that the passions you have shown so far have come together to achieve today’s glory.”
“The successful listing of DreamCIS in Korea Stock Exchange remarks a new starting point for global development and strategy of Tigermed,” said Xiaochun Cao, Co-founder, Executive Director, General Manager of Tigermed. “We will continue to develop global layout and capabilities to serve our customers and partners in Asia Pacific and around the world, and fulfill our commitment of improving health by accelerating the development of innovative and effective treatments for patients everywhere.”
Video of Mrs Gyoungsun Kong, DreamCIS General Manager, Statements
Established in April 2000 in Korea, DreamCIS is a contract research organization (CRO) providingcomprehensive R&D services to biopharmaceutical companies, including clinical trialoperations, post-marketing surveillance and data management. Through the scientific and systematic quality management, DreamCIS is dedicated to satisfy our clients’ needs based on strict ethical consciousness. DreamCIS follows the guidelines of all clinical research services such as KGCP, ICH and DreamCIS’ standard operating procedures (SOPs) to provide the reliability on developing products through the systematic management in clinical research and continuous improvements on quality.
Hangzhou Tigermed Consulting Co., Ltd（stock code: 300347）is a leading Contract Research Organization (CRO) in China dedicated to provide full comprehensive services and solutions for biopharmaceutical research and development. Since inception in 2004, Tigermed has always embraced state-of-the-art technologies and has engaged in partnerships to accelerate medical product development with costs efficiency and high quality.
Headquartered in Hangzhou, Tigermed operates over 60 subsidiaries and 100 offices across China, and established operation sites in over 10 overseas countries such as US, Korea, Japan, Malaysia, and Europe with approximately 5,000 full time employees.